Despite the recent failure of anti-PD-1/PD-L1 therapy in MSS CRC patients, novel bispecific T cell engagers (TCEs) have been developed and tested in treating CRC both in vitro and in vivo. This evidence concerns the gene CD274 and colorectal carcinoma.